HDAC6 inhibitor treatment will prevent tau aggregation and stop or slow the progression of AD
Acetylated tau proteins provide structure to microtubules and support axonal transport.
HDAC6 deacetylates tau, which becomes unbound from microtubules. Free tau becomes phosphorylated.
Eventually, tau becomes hyper-phosphorylated, which leads to neurofibrillary tangles(NFTs).
microtubules fail to
function and eventually neurons die.
HDAC6 inhibitor treatment will preserve axonal transport and stop or slow the progression of AD and ALS
Neurons contain microtubules, which perform important transport functions.
Acetylated tau and tubulin proteins provide structure to microtubules and support axonal transport
HDAC6 deacetylates tau and tubulin, which makes microtubules less resilient and axonal transport is disrupted.
Extensive data from multiple research groups support Eikonizo’s approach for using HDAC6 inhibitors as a disease-modifying therapeutic for neurodegeneration in AD and ALS
HDAC6 deacetylates tau and tubulin, engaging key mechanisms relevant in neurodegeneration